Onconic Therapeutics (476060) stock
KOSDAQ · Pharmaceuticals
As of Nov 16, 2:37 PM KST
- Market cap
- KRW 549 billion
- As of Nov 16, 2026
- P/E
- 22.64x
- Trailing twelve months
- P/B
- 6.40x
- Latest reported equity
- P/S
- 6.68x
- Trailing twelve months
- ROE
- 28.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 549 billion
- As of Nov 16, 2026
- P/E
- 22.64x
- Trailing twelve months
- P/B
- 6.40x
- Latest reported equity
- P/S
- 6.68x
- Trailing twelve months
- ROE
- 28.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
22.64x
P/B
6.40x
P/S
6.68x
Earnings and dividend metrics▾
Earnings
EPS
KRW 534
Earnings per share
BPS
KRW 1,889
Book value per share
ROE
28.3%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 534 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 1,889 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 28.3%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Separate · Filed Aug 12, 2026 | KRW 24.4 billion | KRW 2.8 billion | KRW 3.8 billion | — |
| Q1 2026Separate · Filed May 11, 2026 | KRW 23 billion | KRW 4.6 billion | KRW 6.4 billion | +150.6% |
| Q4 2025Separate · Filed Mar 13, 2026 | KRW 15.6 billion | KRW 1.6 billion | KRW 4.7 billion | — |
| Q3 2025Separate · Filed Nov 11, 2025 | KRW 19.2 billion | KRW 8.3 billion | KRW 9.4 billion | — |
| Q2 2025Separate · Filed Aug 11, 2025 | KRW 9.4 billion | KRW 1.1 billion | -KRW 200 million | — |
| Q1 2025Separate · Filed May 12, 2025 | KRW 9.2 billion | KRW 1.6 billion | KRW 1.9 billion | — |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Separate · Filed Mar 13, 2026 | KRW 53.4 billion | KRW 12.6 billion | KRW 15.8 billion | +259.8% |
| FY2024Separate · Filed Mar 14, 2025 | KRW 14.8 billion | -KRW 4.8 billion | -KRW 8.1 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 6.01%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 320 million
- Previous 20-day average 2.74%
- Net short position
- 405,268 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 2,065,125 shares
- As of Nov 13, 2026 · 4.55% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 6.01% | KRW 320 million |
| Nov 12, 2026 | 3.89% | KRW 100 million |
| Nov 11, 2026 | 2.89% | KRW 90 million |
| Nov 10, 2026 | 1.25% | KRW 30 million |
| Nov 9, 2026 | 1.57% | KRW 50 million |
| Nov 6, 2026 | 1.12% | KRW 40 million |
| Nov 5, 2026 | 2.38% | KRW 90 million |
| Nov 4, 2026 | 0.25% | KRW 10 million |
| Nov 3, 2026 | 3.14% | KRW 80 million |
| Nov 2, 2026 | 1.07% | KRW 20 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Resolution to Convene a Shareholders Meeting (Extraordinary General Meeting)Oct 16, 2026 · Shareholders MeetingEnglish
- Proxy Solicitation Reference DocumentOct 16, 2026 · Proxy SolicitationEnglish
- Technology or Regulatory Approval(Korean)Sep 2, 2026
- Technology or Regulatory Approval(Korean)Jul 14, 2026
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Jul 3, 2026 · Insider Ownership Report
- Technology or Regulatory Approval(Korean)Jul 2, 2026
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Jun 12, 2026 · Insider Ownership Report
- Technology or Regulatory Approval(Korean)Jun 10, 2026
Filings with a published English version open in English; the rest link to the Korean original.
Onconic Therapeutics (476060) stock information
KOSDAQ
Onconic Therapeutics (476060) is listed on KOSDAQ. Its market capitalization is about KRW 549 billion. On trailing-twelve-month earnings the P/E ratio is 22.64, and the P/B ratio is 6.4. Return on equity is 28.3%. These figures are computed in-house from official filings and are reference information only.
Onconic Therapeutics — frequently asked questions
- What is the P/E ratio of Onconic Therapeutics (476060)?
- On a trailing-twelve-month basis, 476060 trades at a P/E ratio of 22.64. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Onconic Therapeutics?
- 476060 has a market capitalization of about KRW 549 billion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.